Martin S. Tallman

Midwestern University — United States

Medicine · Health Sciences

133h-index87.6kcitations1.3kworks10.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(762), Acute Lymphoblastic Leukemia research(351), Retinoids in leukemia and cellular processes(256), Chronic Lymphocytic Leukemia Research(202), Chronic Myeloid Leukemia Treatments(190)

Publications1.3k total

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Blood Advances·2025· 1 citedOpen Access
Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation
Blood·2025
Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries
Blood·2025
Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles
Blood·2025Open Access
Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study
Blood·2025
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Blood·2025
Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.
Blood·2025
Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials
Blood·2025
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Blood·2025Open Access
The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival
Blood·2025Open Access
Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Leukemia & lymphoma/Leukemia and lymphoma·2025
Curative strategies for high-risk acute promyelocytic leukemia
Current Opinion in Oncology·2025· 2 cited
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
Cancer·2025· 1 citedOpen Access
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
UNC Libraries·2025Open Access
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
UNC Libraries·2025Open Access
Effects of heat therapy on exercise tolerance in a rat model of heart failure with preserved ejection fraction
Journal of Applied Physiology·2025· 2 citedOpen Access
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant
Blood Advances·2025· 1 citedOpen Access
Patients with AML and an <i>IDH2-R172</i> mutation exhibit a unique initial response to intensive chemotherapy induction
Blood Advances·2025· 2 citedOpen Access
Patients with high-risk acute promyelocytic leukemia need maintenance therapy for one yearthe PROS
Haematologica·2025Open Access
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Blood Advances·2025· 4 citedOpen Access
page 1 of 65Next →

Frequent Co-authors

Elisabeth Paietta(15), Richard M. Stone(14), Mark R. Litzow(13), Frederick R. Appelbaum(12), Jacob M. Rowe(12), Richard A. Larson(11), Ross L. Levine(10), Bob Löwenberg(9), Selina M. Luger(9), Hagop M. Kantarjian(9), Clara D. Bloomfield(8), Jessica K. Altman(8), Hartmut Döhner(7), Miguel Á. Sanz(7), Hillard M. Lazarus(7), Elihu H. Estey(6), Francesco Lo‐Coco(6), Jorge Sierra(6), Eytan M. Stein(6), Cheryl L. Willman(6)